Ventyx Biosciences/VTYX

$4.67

1.52%
-
1D1W1MYTD1YMAX

About Ventyx Biosciences

Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of small molecule product candidates to address a range of inflammatory diseases with unmet need. The Company’s pipeline includes VTX002 (S1P1R Modulator), VTX958 (TYK2 Inhibitor), and VTX2735 and VTX3232 (NLRP3 Inhibitor Portfolio). VTX002 is a sphingosine 1 phosphate receptor (S1P1R) modulator in Phase II development for patients with moderately to severely active ulcerative colitis (UC). VTX958 is an oral, selective clinical-stage inhibitor of tyrosine kinase type 2 (TYK2), an intracellular signaling kinase in the Janus kinase (JAK) family that regulates chronic inflammation in immune-mediated diseases. Its third product candidate, VTX2735, is a peripheral-targeted NOD-like receptor protein 3 (NLRP3) inflammasome inhibitor. In addition to VTX2735, it is also developing VTX3232, its lead CNS-penetrant NLRP3 inhibitor in Phase 1 development.

Ticker

VTYX

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Raju Mohan

Employees

79

Headquarters

San diego, United States

VTYX Metrics

BasicAdvanced
$323.96M
Market cap
-
P/E ratio
-$3.29
EPS
-
Beta
-
Dividend rate
$323.96M
$40.58
$1.87
4.08M
11.873
-59.46%
-64.56%
-63.22%
1.117
1.328
-60.44%

What the Analysts think about VTYX

Analyst Ratings

Majority rating from 10 analysts.
Buy

Price Targets

Average projection from 10 analysts.
131.26% upside
High $21.00
Low $5.00
$4.67
Current price
$10.80
Average price target

VTYX Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$0
-
Net income
$-46.7M
-13.52%
Profit margin
0%
-

VTYX Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 12.55%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.68
-$0.91
-$0.92
-$0.79
-
Expected
-$0.65
-$0.71
-$0.90
-$0.90
-$0.69
Surprise
4.97%
27.97%
2.73%
-12.55%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Ventyx Biosciences stock?

Ventyx Biosciences (VTYX) has a market cap of $323.96M as of April 15, 2024.

What is the P/E ratio for Ventyx Biosciences stock?

The price to earnings (P/E) ratio for Ventyx Biosciences (VTYX) stock is 0 as of April 15, 2024.

Does Ventyx Biosciences stock pay dividends?

No, Ventyx Biosciences (VTYX) stock does not pay dividends to its shareholders as of April 15, 2024.

When is the next Ventyx Biosciences dividend payment date?

Ventyx Biosciences (VTYX) stock does not pay dividends to its shareholders.

What is the beta indicator for Ventyx Biosciences?

Ventyx Biosciences (VTYX) does not currently have a Beta indicator.

What is the Ventyx Biosciences stock price target?

The target price for Ventyx Biosciences (VTYX) stock is $10.8, which is 131.26% above the current price of $4.67. This is an average based on projections from 10 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Ventyx Biosciences stock

Buy or sell Ventyx Biosciences stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing